Back to top
more

Arbutus Biopharma (ABUS)

(Delayed Data from NSDQ)

$2.78 USD

2.78
626,057

+0.05 (1.83%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $2.78 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates

Arbutus Biopharma (ABUS) provides updates on its HBV development programs. However, uncertainty and early to mid-stage of development remains a concern.

    Are Options Traders Betting on a Big Move in Arbutus (ABUS) Stock?

    Investors need to pay close attention to Arbutus (ABUS) stock based on the movements in the options market lately.

      Arbutus Biopharma (ABUS) Shares March Higher, Can It Continue?

      As of late, it has definitely been a great time to be an investor in Arbutus Biopharma Corporation (ABUS)

        5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates

        Biotech industry experiences a turnaround in June. Here are five stocks which are expected to beat expectation in Q2.

          Arbutus Biopharma (ABUS) Jumps: Stock Rises 9.6%

          Arbutus Biopharma (ABUS) was a big mover last session, as the company saw its shares rise more than 9% on the day, amid huge volumes.

            Alexion to Restructure Operations, to Lower Headcount by 20%

            Alexion Pharmaceuticals, Inc. (ALXN) announced that it will undertake a restructuring plan to re-align the global organization and cut workforce.

              Alexion (ALXN) Licenses Artubus Technology for Rare Diseases

              Alexion Pharmaceuticals, Inc. (ALXN) has recently licensed Arbutus Biopharma proprietary LNP technology for use in rare disease programs.

                Celgene Issues Preliminary 2016 Results, Lifts 2017 View

                Celgene (CELG) announced preliminary 2016 results and upped guidance for 2017 at the J.P. Morgan Healthcare Conference.

                  Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments

                  Ionis (IONS) entered into a collaboration agreement with Novartis (NVS) for the development and commercialization of AKCEA-APO(a)-L and AKCEA-APOCIII-L.

                    Alexion Blood Disorder Drug Gets Orphan Designation in U.S.

                    Alexion (ALXN) announced that the FDA has granted orphan drug designation to ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

                      The Medicines Co LDL-Lowering Drug Positive in Phase II

                      The Medicines Company (MDCO) announced positive top-line results from a Day 180 interim analysis of the ongoing ORION-1 phase II study on its pipeline candidate, Inclisiran (formerly PCSK9si), for the treatment of hypercholesterolemia.

                        Ultragenyx's (RARE) KRN23 Accepted for Review in the EU

                        Ultragenyx (RARE) announced that EMA has accepted to review its MAA for KRN23 for the treatment of X-linked hypophosphatemia.

                          Bayer's sNDA for Stivarga Granted Priority Review in the U.S.

                          Bayer (BAYRY) announced that the FDA has granted priority review designation to its sNDA for Stivarga for the second-line treatment of patients with uHCC.

                            Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data

                            Ionis (IONS) announced positive data from a phase II study on IONIS-GCGR for the treatment of patients with type II diabetes.

                              Innocoll (INNL) Down on FDA's Refusal to File Xaracoll NDA

                              Innocoll (INNL) announced that it has received a Refusal to File letter from the FDA in connection with the NDA for Xaracoll for the treatment of postsurgical pain.

                                Fortress Biotech (FBIO) in Focus: Stock Moves 20.9% Higher

                                Fortress Biotech, Inc. (FBIO) moved big last session, as its shares jumped almost 21% on the day.

                                  Galena Biopharma Reveals Regulatory Pathway for GALE-401

                                  Galena (GALE) confirmed the regulatory pathway to advance GALE-401 (anagrelide CR) into a pivotal phase III study.

                                    Intercept Pharmaceuticals (ICPT) Jumps: Stock Rises 9.3%

                                    Intercept Pharmaceuticals, Inc. (ICPT) shares rose over 9% in the last trading session.

                                      Anthera (ANTH) Stock Falls on Poor Phase III Sollpura Data

                                      Anthera (ANTH) reported unimpressive top-line data from a phase III study on Sollpura in cystic fibrosis patients with exocrine pancreatic insufficiency.

                                        NewLink Genetics (NLNK) Jumps: Stock Adds 10% in Session

                                        NewLink Genetics Corporation (NLNK) shares rose almost 10% in the last trading session.

                                          Alexion Soliris Fails in Phase II/III Delayed Graft Function Study

                                          Alexion (ALXN) reported poor top-line data from a phase II/III PROTECT study on Soliris for the prevention of delayed graft function after kidney transplantation.

                                            Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy

                                            Bristol-Myers (BMY) inks a deal with PsiOxus for an early-stage oncolytic virus candidate, NG-348.

                                              Celgene (CELG) Otezla Approved in Japan for Two Indications

                                              Celgene's (CELG) Otezla approved for the treatment of plaque psoriasis and psoriatic arthritis in Japan.

                                                Roche Presents Positive Follicular Lymphoma Data on Gazvya

                                                Roche Holding AG (RHHBY) announced encouraging data from the pivotal phase III study, GALLIUM.

                                                  Pfizer Leukemia Drug Meets Primary Endpoint in Phase III

                                                  Pfizer Inc. (PFE) and partner Avillion LLP announced that a phase III study (BFORE) evaluating its marketed drug Bosulif in the first-line setting met the primary endpoint